Introduction: Risk stratification of laboratory developed tests (LDTs) has been proposed as a fundamental component in their regulatory oversight. Few LDT regulatory proposals, however, include examples of stratification for common and/or esoteric tests. We recently conducted a risk stratification exercise, attempting to classify representative LDTs using separate stratification methods proposed by the Food and Drug Administration and three professional organizations. As the New York State Department of Health (NYDOH) has recently implemented rules for regulating LDTs that include risk stratification criteria, the objective of the present study was to apply NYDOH LDT risk stratification criteria to the same four representative LDTs, and evaluate NYDOH criteria for overall ease of use, clarity, and stratification outcome. Methods: Four representative LDTs (BCR-ABL1 mutation by next generation sequencing, serotonin release assay, cytomegalovirus by quantitative PCR, and ERBB2 [Her2] by immunohistochemistry) were selected to represent a variety of methodologies and clinical applications. A risk stratification exercise was conducted applying NYDOH criteria to these four tests. NYDOH criteria include determination of 1) whether a methodology is "well-established," b) whether information is a "key determinant" in clinical care, and c) whether an incorrect result would have a "high impact." Results: In this evaluation, all four tests were classified as moderate risk using NYDOH criteria, as all tests used "well-established" methodologies, are "key determinants," and would have "high impact" on patient care if an incorrect result were reported. Criteria were in general clearly defined and relatively easy to apply.
Conclusions: Characterization of a methodology as "well-established" precludes any LDT from being considered high risk in the NYDOH stratification criteria. Characterization of "key determinant" and "impact" were somewhat subjective, as they may also relate to overall clinical management, which varies by provider and clinical context. Objectives: Amyloidosis is an uncommon cause of CHF, and it is now possible to define its etiology at the molecular level. We present the case of a 68-year-old AfricanAmerican male veteran who presented to the emergency department with dyspnea and anasarca. An ECHO study indicated severe ventricular dysfunction (EF 30%) and identified changes ("speckling") suspicious for the presence of amyloid material. The patient was unaware of any family history of cardiomyopathy. Methods: Abdominal fat pad and endomyocardial biopsy were focally positive for apple green birefringence using polarized light following Congo red staining. Molecular studies (ARUP, Salt Lake City, UT) indicated homozygosity for a mutation in the transthyretin (TTR) gene reported to have a frequency of 3%-4% in the AfricanAmerican population in the US but to be non-detectable in the Caucasian population. Assay using HPLC-MS on the endomyocardial biopsy material (Mayo Medical Labs, Rochester, MN) confirmed TTR deposition. Results: Presently cardiac transplantation is the only treatment option available for TTR-mutation related cardiac amyloidosis. The patient however was deemed an unsuitable candidate for transplant in part because, as stated, "his caregiver situation [was] difficult; [he was] separated from [his] wife, and she and [their] children work and cannot afford to stop working to be with him." This citation raises the question of whether eligibility for transplant is determined, at least, in part, by the income of prospective recipient being sufficiently high to afford the presence of an on-site caregiver.
Conclusion:
This case raises some fundamental issues of transplantation criteria in the US system of medical care.
